254 related articles for article (PubMed ID: 27015118)
1. mTOR inhibition as an adjuvant therapy in a metastatic model of HPV+ HNSCC.
Coppock JD; Vermeer PD; Vermeer DW; Lee KM; Miskimins WK; Spanos WC; Lee JH
Oncotarget; 2016 Apr; 7(17):24228-41. PubMed ID: 27015118
[TBL] [Abstract][Full Text] [Related]
2. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
[TBL] [Abstract][Full Text] [Related]
3. Metastatic model of HPV+ oropharyngeal squamous cell carcinoma demonstrates heterogeneity in tumor metastasis.
Vermeer DW; Coppock JD; Zeng E; Lee KM; Spanos WC; Onken MD; Uppaluri R; Lee JH; Vermeer PD
Oncotarget; 2016 Apr; 7(17):24194-207. PubMed ID: 27013584
[TBL] [Abstract][Full Text] [Related]
4. mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.
Molinolo AA; Marsh C; El Dinali M; Gangane N; Jennison K; Hewitt S; Patel V; Seiwert TY; Gutkind JS
Clin Cancer Res; 2012 May; 18(9):2558-68. PubMed ID: 22409888
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
6. Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation.
Shen YQ; Guerra-Librero A; Fernandez-Gil BI; Florido J; García-López S; Martinez-Ruiz L; Mendivil-Perez M; Soto-Mercado V; Acuña-Castroviejo D; Ortega-Arellano H; Carriel V; Diaz-Casado ME; Reiter RJ; Rusanova I; Nieto A; López LC; Escames G
J Pineal Res; 2018 Apr; 64(3):. PubMed ID: 29247557
[TBL] [Abstract][Full Text] [Related]
7. Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Aderhold C; Faber A; Umbreit C; Birk R; Weiss C; Sommer JU; Hörmann K; Schultz JD
Anticancer Res; 2015 Apr; 35(4):1951-9. PubMed ID: 25862847
[TBL] [Abstract][Full Text] [Related]
8. Differential anticancer activities of arsenic trioxide on head and neck cancer cells with different human papillomavirus status.
Du S; Liu K; Gao P; Li Z; Zheng J
Life Sci; 2018 Nov; 212():182-193. PubMed ID: 30243648
[TBL] [Abstract][Full Text] [Related]
9. Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models.
Ekshyyan O; Moore-Medlin TN; Raley MC; Sonavane K; Rong X; Brodt MA; Abreo F; Alexander JS; Nathan CA
BMC Cancer; 2013 Jul; 13():320. PubMed ID: 23815869
[TBL] [Abstract][Full Text] [Related]
10. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer.
Biktasova A; Hajek M; Sewell A; Gary C; Bellinger G; Deshpande HA; Bhatia A; Burtness B; Judson B; Mehra S; Yarbrough WG; Issaeva N
Clin Cancer Res; 2017 Dec; 23(23):7276-7287. PubMed ID: 28916527
[No Abstract] [Full Text] [Related]
11. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
12. Significance of mammalian target of rapamycin in patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil.
Li SH; Lin WC; Huang TL; Chen CH; Chiu TJ; Fang FM; Huang WT; Hsu CM; Luo SD; Lai CC; Su YY; Chuang HC; Chien CY
Head Neck; 2016 Apr; 38 Suppl 1():E844-52. PubMed ID: 25917382
[TBL] [Abstract][Full Text] [Related]
13. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.
Kumar B; Yadav A; Lang JC; Cipolla MJ; Schmitt AC; Arradaza N; Teknos TN; Kumar P
Mol Cancer Ther; 2012 Sep; 11(9):1988-98. PubMed ID: 22723337
[TBL] [Abstract][Full Text] [Related]
14. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.
Sun ZJ; Zhang L; Hall B; Bian Y; Gutkind JS; Kulkarni AB
Clin Cancer Res; 2012 Oct; 18(19):5304-13. PubMed ID: 22859719
[TBL] [Abstract][Full Text] [Related]
15. Mammalian target of rapamycin inhibitors as possible adjuvant therapy for microscopic residual disease in head and neck squamous cell cancer.
Nathan CO; Amirghahari N; Rong X; Giordano T; Sibley D; Nordberg M; Glass J; Agarwal A; Caldito G
Cancer Res; 2007 Mar; 67(5):2160-8. PubMed ID: 17332346
[TBL] [Abstract][Full Text] [Related]
16. Combination of mTOR and EGFR targeting in an orthotopic xenograft model of head and neck cancer.
Bozec A; Ebran N; Radosevic-Robin N; Sudaka A; Monteverde M; Toussan N; Etienne-Grimaldi MC; Nigro CL; Merlano M; Penault-Llorca F; Milano G
Laryngoscope; 2016 Apr; 126(4):E156-63. PubMed ID: 26597440
[TBL] [Abstract][Full Text] [Related]
17. Prevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.
Madera D; Vitale-Cross L; Martin D; Schneider A; Molinolo AA; Gangane N; Carey TE; McHugh JB; Komarck CM; Walline HM; William WN; Seethala RR; Ferris RL; Gutkind JS
Cancer Prev Res (Phila); 2015 Mar; 8(3):197-207. PubMed ID: 25681087
[TBL] [Abstract][Full Text] [Related]
18. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
[TBL] [Abstract][Full Text] [Related]
19. Systemic Treatment in HPV-Induced Recurrent or Metastatic HNSCC.
Rieke DT; Keilholz U
Recent Results Cancer Res; 2017; 206():149-160. PubMed ID: 27699536
[TBL] [Abstract][Full Text] [Related]
20. Lupeol suppresses cisplatin-induced nuclear factor-kappaB activation in head and neck squamous cell carcinoma and inhibits local invasion and nodal metastasis in an orthotopic nude mouse model.
Lee TK; Poon RT; Wo JY; Ma S; Guan XY; Myers JN; Altevogt P; Yuen AP
Cancer Res; 2007 Sep; 67(18):8800-9. PubMed ID: 17875721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
